![Elena Feinstein](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Elena Feinstein
Hoofd Techniek/Wetenschap/O&O bij Quark Pharmaceuticals, Inc.
Profiel
Elena Feinstein is currently the Chief Scientific Officer at Quark Pharmaceuticals, Inc. She holds a doctorate degree from Weizmann Institute of Science and Moscow University.
Actieve functies van Elena Feinstein
Bedrijven | Functie | Begin |
---|---|---|
Quark Pharmaceuticals, Inc.
![]() Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Hoofd Techniek/Wetenschap/O&O | 01-01-1998 |
Opleiding van Elena Feinstein
Moscow University | Doctorate Degree |
Weizmann Institute of Science | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Quark Pharmaceuticals, Inc.
![]() Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |